Suggested remit: To appraise the clinical and cost effectiveness of relugolix–estradiol–norethisterone acetate within its marketing authorisation for treating pain associated with endometriosis.
Status
|
In progress
|
Technology type
|
Medicine
|
Decision
|
Selected
|
Process |
STA Standard
|
ID number |
3982
|
Project Team
Email enquiries
External Assessment Group |
Kleijnen Systematic Reviews Ltd |
Stakeholders
Companies sponsors |
Gedeon Richter (relugolix) |
Others |
Department of Health and Social Care |
|
NHS England |
Professional groups |
Royal College of Physicians |
Comparator companies |
Bayer – CAU not returned, not participating |
|
Besins Healthcare (progesterone) |
|
Lupin Healthcare – CAU not returned, not participatin |
|
Morningside Healthcare – CAU not returned, not participating |
|
Mylan– CAU not returned, not participating |
|
Organon Pharma– CAU not returned, not participating |
|
Pfizer – CAU not returned, not participating |
|
Theramex (combined hormonal contraception) |
General commentators |
All Wales Therapeutics and Toxicology Centre |
|
British National Formulary |
|
Department of Health - Northern Ireland |
|
Healthcare Improvement Scotland |
|
Medicines and Healthcare products Regulatory Agency |
|
Scottish Medicines Consortium |
|
Welsh Government |
|
Welsh Health Specialised Services Committee |
Date
|
Update
|
22 May 2024
|
Declaration of interests |
28 March 2024 - 22 April 2024
|
Draft guidance |
07 March 2024
|
Committee meeting |
03 August 2023
|
Invitation to participate |
28 March 2023
|
Following the changes to remove technical engagement as standard from appraisal timelines, the timelines for the appraisal of Relugolix–estradiol–norethisterone acetate for treating pain associated with endometriosis have been revised. It is anticipated that the appraisal will begin in early-August 2023 when we will write to you about how you can get involved. |
23 January 2023 - 20 February 2023
|
Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
23 January 2023
|
In progress. Scoping commenced |
22 November 2022
|
As you will be aware, the Department for Health & Social Care has asked NICE to conduct an appraisal of Relugolix–estradiol–norethisterone acetate for treating pain from endometriosis.
Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in late July 2023. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission. |
For further information on our processes and methods, please see our CHTE processes and methods manual